Semi-quantitative assessment of 111 melanoma specimens revealed a correlation between PDPN and PD-L1 expression (overall co-expression 46.1%, p < 0.05), with disease stage-specific disparities: PDPN prevalence was higher in primary lesions (61.6%) than in metastases (43.8%), whereas PD-L1 expression was elevated in metastatic lesions (87.5%) compared to primary tumors (61.6%). This evidence concerns the gene PDPN and melanoma.